Guardant Health. has been granted a patent for methods to assess homologous recombination repair deficiency (HRD) in cancer patients. The patent outlines a process for determining HRD status using cell-free DNA and administering immunological therapies based on the HRD score, indicating potential treatment responsiveness. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of June 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for determining hrd status and treating cancer
The patent US12031186B2 outlines a method for treating cancer in subjects identified as having homologous recombination deficiency (HRD) positive status. The process begins with obtaining a biological sample, specifically cell-free DNA (cfDNA), from the subject. A diagnostic assay is then performed to determine an HRD score, which involves analyzing sequence data to assess coverage data, identify breakpoints linked to fusion events, and detect deletions associated with specific genes. If the HRD score exceeds a predetermined threshold, the subject is classified as HRD positive, allowing for the administration of an immunological therapeutic agent tailored to their cancer type.
The claims further detail the methodology, including the sequencing of homologous recombination repair (HRR) genes and the use of algorithms to analyze coverage data for identifying genetic alterations. The patent specifies various HRR genes that may be involved, such as BRCA1, BRCA2, and ATM. Additionally, it describes the process of determining breakpoints and deletions, employing techniques like circular binary segmentation. The method also encompasses the annotation of genetic variants and the calculation of a maximum somatic allele fraction (MSAF). Notably, the immunological therapeutic agent may be combined with a poly (ADP-ribose) polymerase (PARP) inhibitor, with specific examples provided, including OLAPARIB and TALAZOPARIB. This innovative approach aims to enhance treatment efficacy for patients with HRD-positive cancers.
To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
